AI & Biopharma – A Quick Take from Amgen

The importance of AI for Biopharma, in the view of Alexion (AstraZeneca’s rare disease unit), and how the company is using it.

Citi’s Adam Spielman is the author of a series of reports on the impact of AI on the healthcare sector. Here he discusses several aspects of his research including AI’s impact on clinicians, its potential to drastically lessen their administrative burden, and why biopharma could be the area that AI impacts most of all.